I. Examination related to immune damage in neurological diseases (blood and cerebrospinal fluid paired specimens required) 1. CSF oligoclonal band (OCB) 2. blood oligoclonal band (OCB) 3. synthesis rate (IgG-Syn) determination 4. index determination 5. blood-brain barrier 6. myelin basic protein (MBP) determination 7. blood myelin basic protein (MBP) determination 8. myelin basic protein auto Antibodies 9, blood myelin basic protein autoantibodies 10, anti-myelin oligodendrocyte glycoprotein antibodies (MOG ab) 11, blood anti-myelin oligodendrocyte glycoprotein antibodies (MOG ab) 12, anti-water channel protein antibodies (AQP4.Ab/NMO-IgG) 13, blood anti-water channel protein antibodies (AQP4.Ab/NMO-IgG) 2, myasthenia gravis: 1 Ab, acetylcholine receptor antibody (AchR.Ab) 2, acetylcholinesterase antibody (AchE.Ab) determination (blood specimen) 3, anti-linker antibody (or anti-myosin antibody, Titin.Ab) 4, anti-Ryanodine receptor antibody RyR.Ab 3, peripheral neuropathy, polymyositis, paraneoplastic syndrome: ganglioside Lipid spectrum antibody assay (blood and/or cerebrospinal fluid specimens), polymyositis spectrum antibody (blood specimens), paraneoplastic syndrome (Hu, Yo, Ri antibodies, blood and/or cerebrospinal fluid specimens) IV. Flow cytology assay (research project will soon enter clinical routine): T and B lymphocyte subpopulation assay (CD4, CD 8, CD 3, CD69, CD5, CD19, etc.)